Abstract
Alexander Cole has been investigating two aspects of innate host defense. The first area examines the natural ability of human airway secretions to prevent pathogenic bacterial colonization and aims to identify the host substances that mediate the innate resistance to colonization. His group is examining the host defense of the airways of donors who are healthy and donors who are persistent nasal carriers of Staphylococcus aureus. Their studies to date suggest that a defect exists in the nasal fluid of carriers that permits the colonization of S. aureus in their nasal passages. Ongoing studies to resolve the molecular determinants of S. aureus nasal carriage include a proteomic approach to identify molecules that are dysregulated in S. aureus carrier fluid. Their second focus is based on the reconstruction (from an expressed pseudogene) of a human antimicrobial peptide, called “retrocyclin”, homologous to rhesus monkey circular minidefensins. The peptide had a remarkable ability to inhibit proviral DNA formation and to protect immortalized and primary human CD4+ lymphocytes from in vitro infection by both X4 and R5 strains of HIV-1. Current goals include characterizing retrocyclins antiretroviral mechanism of action, testing the activity, stability and toxicity of retrocyclin in human fluids, and constructing next-generation analogs for use as antimicrobial therapeutics and preventatives. REPRESENTATIVE PUBLICATIONS 1. Cole, A.M., T. Hong, L.M. Boo, T. Nguyen, C. Zhao, G. Bristol, J.A. Zack, A.J. Waring, O.O. Yang, and R.I. Lehrer. (2002). Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA 99(4): 1813-1818. 2. Cole, A.M., H-I. Liao, O. Stuchlik, J. Tilan, J. Pohl, and T. Ganz. (2002). Cationic polypeptides are required for antimicrobial activity of human airway fluid. J. Immunol. 169(12): 6985-6991. 3. Ganz, T., V. Gabayan, H.-I. Liao, L. Liu, A. Oren, T. Graf, and A.M. Cole. (2003). Increased pathogenicity of Micrococcus luteus in lysozyme M-deficient mice. Blood 101(6): 2388-2392. 4. Cole, A.M. and R.I. Lehrer. (2003). Minidefensins: antimicrobial peptides with activity against HIV-1. Curr. Pharm. Des. 9(18): 1463-1473. 5. Cole, A.M. (2003). Minidefensins and other antimicrobial peptides: candidate anti-HIV microbicides. Expert Opin. Therapeut. Targets. 7(3): 329-341. 6. Cole, A.M., H-I. Liao, T. Ganz, and O.O. Yang. (2003). Defensin-like antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett. 535 (1-3): 195-199. 7. Munk, C., G. Wei, O.O. Yang, A.J. Waring, W. Wang, T. Hong, R.I. Lehrer, N.R. Landau and A.M. Cole. (2003). The theta-defensin, Retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses 19(10): 875-882. 8. Wang, W., S.M. Owen, D.L. Rudolph, A.M. Cole, T. Hong, A.J. Waring, R.B. Lal. and R.I. Lehrer. (2004). Activity of alpha and theta defensins against primary isolates of HIV-1. J. Immunol. 173(1): 515-520. 9. Kalfa, V.C., S.L. Spector, T. Ganz, and A.M. Cole. (2004). Patients with perennial allergic rhinitis and recurrent sinusitis have reduced lysozyme levels in their nasal secretions. Ann. Allergy Asthma Immunol. 93(3): 288-292. 10. Cole, A.M., W. Wang, A.J. Waring, and R.I. Lehrer. (2004). Retrocyclins: using past as prologue. Curr. Prot. & Peptide Sci. 5(5): 373-381.
Combinatorial Chemistry & High Throughput Screening
Title: Meet The Guest Editor
Volume: 8 Issue: 3
Author(s): Alexander M. Cole
Affiliation:
Abstract: Alexander Cole has been investigating two aspects of innate host defense. The first area examines the natural ability of human airway secretions to prevent pathogenic bacterial colonization and aims to identify the host substances that mediate the innate resistance to colonization. His group is examining the host defense of the airways of donors who are healthy and donors who are persistent nasal carriers of Staphylococcus aureus. Their studies to date suggest that a defect exists in the nasal fluid of carriers that permits the colonization of S. aureus in their nasal passages. Ongoing studies to resolve the molecular determinants of S. aureus nasal carriage include a proteomic approach to identify molecules that are dysregulated in S. aureus carrier fluid. Their second focus is based on the reconstruction (from an expressed pseudogene) of a human antimicrobial peptide, called “retrocyclin”, homologous to rhesus monkey circular minidefensins. The peptide had a remarkable ability to inhibit proviral DNA formation and to protect immortalized and primary human CD4+ lymphocytes from in vitro infection by both X4 and R5 strains of HIV-1. Current goals include characterizing retrocyclins antiretroviral mechanism of action, testing the activity, stability and toxicity of retrocyclin in human fluids, and constructing next-generation analogs for use as antimicrobial therapeutics and preventatives. REPRESENTATIVE PUBLICATIONS 1. Cole, A.M., T. Hong, L.M. Boo, T. Nguyen, C. Zhao, G. Bristol, J.A. Zack, A.J. Waring, O.O. Yang, and R.I. Lehrer. (2002). Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA 99(4): 1813-1818. 2. Cole, A.M., H-I. Liao, O. Stuchlik, J. Tilan, J. Pohl, and T. Ganz. (2002). Cationic polypeptides are required for antimicrobial activity of human airway fluid. J. Immunol. 169(12): 6985-6991. 3. Ganz, T., V. Gabayan, H.-I. Liao, L. Liu, A. Oren, T. Graf, and A.M. Cole. (2003). Increased pathogenicity of Micrococcus luteus in lysozyme M-deficient mice. Blood 101(6): 2388-2392. 4. Cole, A.M. and R.I. Lehrer. (2003). Minidefensins: antimicrobial peptides with activity against HIV-1. Curr. Pharm. Des. 9(18): 1463-1473. 5. Cole, A.M. (2003). Minidefensins and other antimicrobial peptides: candidate anti-HIV microbicides. Expert Opin. Therapeut. Targets. 7(3): 329-341. 6. Cole, A.M., H-I. Liao, T. Ganz, and O.O. Yang. (2003). Defensin-like antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett. 535 (1-3): 195-199. 7. Munk, C., G. Wei, O.O. Yang, A.J. Waring, W. Wang, T. Hong, R.I. Lehrer, N.R. Landau and A.M. Cole. (2003). The theta-defensin, Retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses 19(10): 875-882. 8. Wang, W., S.M. Owen, D.L. Rudolph, A.M. Cole, T. Hong, A.J. Waring, R.B. Lal. and R.I. Lehrer. (2004). Activity of alpha and theta defensins against primary isolates of HIV-1. J. Immunol. 173(1): 515-520. 9. Kalfa, V.C., S.L. Spector, T. Ganz, and A.M. Cole. (2004). Patients with perennial allergic rhinitis and recurrent sinusitis have reduced lysozyme levels in their nasal secretions. Ann. Allergy Asthma Immunol. 93(3): 288-292. 10. Cole, A.M., W. Wang, A.J. Waring, and R.I. Lehrer. (2004). Retrocyclins: using past as prologue. Curr. Prot. & Peptide Sci. 5(5): 373-381.
Export Options
About this article
Cite this article as:
Cole M. Alexander, Meet The Guest Editor, Combinatorial Chemistry & High Throughput Screening 2005; 8 (3) . https://dx.doi.org/10.2174/1386207053764585
DOI https://dx.doi.org/10.2174/1386207053764585 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mosquito Allergy and Mosquito Salivary Allergens
Protein & Peptide Letters Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Targeting Allergic Airway Diseases by siRNA: An Option for the Future?
Current Molecular Medicine Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design Pro-inflammatory and Pro-apoptotic Role of IL-33 in the Human Acute Lung Injury (ALI) Development
Current Signal Transduction Therapy MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Evaluation of Topical Black Seed Oil in the Treatment of Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry Leukotrienes and Atherosclerosis
Current Drug Targets The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Predicted Mechanism of Antiasthmatic Drugs in Depression Based on Their Interaction with SERT and 5-HT1A Receptors
Current Enzyme Inhibition Carbon Monoxide: Medicinal Chemistry and Biological Effects
Current Medicinal Chemistry Targeting Th2 Cells in Asthmatic Airways
Current Drug Targets - Inflammation & Allergy Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Strategies for Fibrotic Lung Disease: A Review with a Focus on Epithelial-Mesenchymal Transition
Recent Patents on Inflammation & Allergy Drug Discovery Pharmaceutical Nanotechnology United States Patent Watch (January – March 2016)
Pharmaceutical Nanotechnology Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets